IQVIA Holdings Inc. (0JDM.L)
| Previous close | 256.15 |
| Open | 258.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 258.21 - 258.60 |
| 52-week range | 258.21 - 258.60 |
| Volume | 58 |
| Avg. volume | N/A |
| Market cap | 20.373B |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | 48.67 |
| EPS (TTM) | 2.10 |
| Earnings date | 18 Oct 2021 - 22 Oct 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
IQVIA Holdings' (IQV) Stock Up 44% Year to Date: Here's Why
Encouraging yearly guidance and consecutive better-than-expected top- and bottom-line performances have been aiding IQVIA Holdings' (IQV) stock.
- Zacks
IQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals
IQVIA (IQV) and NRx are set to work closely to support activities essential for emergency use authorization of ZYESAMI.
- Business Wire
IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment
RESEARCH TRIANGLE PARK, N.C., September 13, 2021--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx) (Nasdaq: NRXP). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited
